Research programme: FLT-3 tyrosine kinase inhibitors - Novartis

Drug Profile

Research programme: FLT-3 tyrosine kinase inhibitors - Novartis

Alternative Names: AST 487; FLT-3 tyrosine kinase inhibitors research programme - Novartis; NVP-AST487

Latest Information Update: 11 Aug 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 11 Aug 2011 No development reported - Preclinical for Acute myeloid leukaemia in Switzerland (PO)
  • 20 Apr 2005 Preclinical trials in Acute myeloid leukaemia in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top